Peadar Cremin, Ph.D.

Executive Director, DMPK

Dr. Peadar Cremin has over 20 years of experience working in Drug Metabolism/Pharmacokinetics/ADME and GLP Bioanalytical in small successful Bay Area biotechs. He most recently worked at Cytokinetics, Inc, South San Francisco where he led the DMPK effort which led to the discovery of Aficamten a novel best-in-class Cardiac Myosin Inhibitor for the treatment of Hypertrophic Cardiac Myopathy. Prior to Cytokinetics he has worked at Xenoport, Santa Clara where he provided ADME/transporter/CMC support for novel prodrug programs leading to a successful discovery of XP13512 (Horizant), a novel prodrug of Gabapentin, commercialized for the treatment of restless legs syndrome and postherpetic neuralgia. In addition Dr Cremin has worked in similar roles in Relypsa, Santa Clara and at PTRL West, Hercules. Dr Cremin received his PhD in Organic Chemistry at University College Dublin and his BS from University College Cork, Ireland. He studied Natural Product metabolite elucidation at the Institute of Pharmacognosy and Phytochemistry at the University of Lausanne in Switzerland and completed a post-doc in Bioanalytical methods for the quantitation of anti-oxidant Natural Products and their metabolites in human plasma under the direction of Prof. A. Waterhouse at UC Davis.

Go to Top